<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103051</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08013</org_study_id>
    <secondary_id>EORTC-08013</secondary_id>
    <secondary_id>2004-001332-23</secondary_id>
    <nct_id>NCT00103051</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study With Gefitinib (Sequentially) Following Gemcitabine/Cisplatin as Induction Regimen for Patients With Stage IIIA N2 NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Giving gemcitabine and cisplatin together with gefitinib before surgery may&#xD;
      shrink the tumor so it can be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine and cisplatin together&#xD;
      with gefitinib works in treating patients who are undergoing surgery for stage III non-small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the therapeutic activity of neoadjuvant induction therapy comprising&#xD;
           gemcitabine, cisplatin, and gefitinib in patients with stage IIIA non-small cell lung&#xD;
           cancer undergoing surgery.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the stage downsizing and complete resectability rate in patients with no&#xD;
           progressive disease who undergo surgery after treatment with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, multicenter study.&#xD;
&#xD;
      Patients receive induction therapy comprising gemcitabine IV over 30 minutes on days 1, 8,&#xD;
      22, 29, 43, and 50; cisplatin IV over 3-6 hours on days 2, 23, and 44; and oral gefitinib&#xD;
      once daily on days 51-79. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity. Within 2-7 days after completion of induction therapy, patients with&#xD;
      no progressive disease undergo tumor resection.&#xD;
&#xD;
      After completion of study treatment, patients are followed at least every 3 months for 2&#xD;
      years and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate as measured by RECIST criteria prior to surgery</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate as measured by RECIST criteria prior to surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTC</measure>
  </secondary_outcome>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Clinical stage IIIA by chest CT scan&#xD;
&#xD;
               -  Unresectable N2 disease by mediastinoscopy, mediastinotomy, thoracotomy, or&#xD;
                  video-assisted thoracic surgery&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Planning to undergo lobectomy or pneumonectomy after induction therapy&#xD;
&#xD;
          -  No N3 or metastatic disease by physical exam, thoracic CT scan, bone scan, and CT scan&#xD;
             or ultrasound of the liver and adrenal glands&#xD;
&#xD;
          -  No pleural or pericardial effusion&#xD;
&#xD;
          -  No superior vena cava syndrome&#xD;
&#xD;
          -  No diffuse interstitial pulmonary fibrosis&#xD;
&#xD;
          -  No signs or symptoms of CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.25 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No medically uncontrolled congestive heart failure or angina pectoris&#xD;
&#xD;
          -  No uncontrolled hypertension or arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Physically and mentally fit to receive gemcitabine- and cisplatin-containing&#xD;
             chemotherapy&#xD;
&#xD;
          -  Physiologically fit to undergo surgery&#xD;
&#xD;
          -  No uncontrolled, active infection requiring IV antibiotics&#xD;
&#xD;
          -  No history of hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  No motor or sensory neurotoxicity ≥ grade 2&#xD;
&#xD;
          -  No other primary malignancy within the past 5 years except carcinoma in situ of the&#xD;
             cervix or adequately treated basal cell skin cancer&#xD;
&#xD;
               -  No prior melanoma, breast cancer, or renal cell cancer&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for NSCLC&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent antiestrogen therapy&#xD;
&#xD;
          -  Concurrent replacement steroids and antiemetic steroids allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for NSCLC&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior surgery for NSCLC&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 month since prior and no concurrent investigational agents&#xD;
&#xD;
          -  No other prior therapy for NSCLC&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers, including any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Barbiturates (e.g., phenobarbital)&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent systemic retinoids&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nico Van Zandwijk, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>February 7, 2005</study_first_submitted>
  <study_first_submitted_qc>February 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2005</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

